newsfilter
← Latest News
Business Wire·

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

Data reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and